Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III Trial Assessing the Benefit of the Addition of Isatuximab to Lenalidomide / Bortezomib / Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

Trial Profile

A Randomized Phase III Trial Assessing the Benefit of the Addition of Isatuximab to Lenalidomide / Bortezomib / Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2018

At a glance

  • Drugs Isatuximab (Primary) ; Lenalidomide (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Melphalan; Stem cell therapies
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 15 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 18 Oct 2018.
    • 14 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top